Last updated: February 14, 2026
Overview
NDC 59762-2858 corresponds to a specific drug product, which must be identified to provide an accurate market and price analysis. Based on the NDC’s structure, the product details are as follows:
- Manufacturer: Mylan (subsequently part of Viatris)
- Product: OnabotulinumtoxinA (commonly known as Botox or Botox-related formulations)
The focus is on botulinum toxin type A formulations, widely used for various indications including neurological disorders, muscular conditions, and cosmetic applications.
Market Landscape
Size and Growth
The global botulinum toxin market was valued at approximately $4.72 billion in 2022. Compound annual growth rate (CAGR) estimates range from 7% to 9% over the next five years, driven by expanding clinical indications and increasing aesthetic procedures [1].
Key market drivers include:
- Growing prevalence of neurological disorders such as spasticity, dystonia.
- Surge in aesthetic demand, especially in North America and Europe.
- Expansion into new therapeutic areas like depression and migraines.
Key Competitors
Major players:
- Allergan (AbbVie) – Botox
- Ipsen – Dysport
- Revance – RHA Collection and Daxxify
- Mylan/Viatris – their own formulations, including biosimilars
The competitive landscape sees continuous patent expirations and biosimilar entries, influencing pricing and market share.
Regulatory Status
Viatris’ botulinum toxin product remains approved for multiple indications, including:
- Cervical dystonia
- Blepharospasm
- Hyperhidrosis
- Glabellar lines
Regulatory filings are current in the U.S. (FDA) and other major markets.
Pricing Dynamics
Historical Pricing
Wholesale Acquisition Cost (WAC) for botulinum toxin formulations varies regionally:
- U.S. (2023): Approximate WAC per unit (100 units) ranges $0.85 to $1.20. An average retail price (average selling price, ASP) is typically 20-30% above WAC.
- European markets: Similar unit-based pricing, adjusted for local regulations and market dynamics.
Biosimilar Impact
The entrance of biosimilars has precipitated a 15-25% price reduction in markets where they are available (notably in Europe). In the U.S., bios mimics like Daxxify by Revance challenge established brands in the aesthetic segment, potentially reducing price margins.
Pricing Trends
- Brand-name products maintain premium pricing in therapeutic settings.
- Biosimilars and generics push prices downward.
- Price competition intensifies with expanded indication approvals and biosimilar launches.
Forecast Projections
Pricing Outlook (2024-2028)
| Year |
Estimated WAC per 100 units |
Retail Price per 100 units |
Notes |
| 2024 |
$0.85 - $1.20 |
$1.02 - $1.44 |
Slight price stability; biosimilar market expansion |
| 2025 |
$0.80 - $1.15 |
$0.96 - $1.38 |
Biosimilar entries gain market share |
| 2026 |
$0.78 - $1.10 |
$0.94 - $1.32 |
Price pressures persist, but therapeutic value sustains |
| 2027 |
$0.75 - $1.05 |
$0.90 - $1.26 |
Intense price competition; new indications emerge |
| 2028 |
$0.73 - $1.00 |
$0.88 - $1.20 |
Market stabilization at lower price points |
Influencing Factors
- Biosimilar approval timeline and uptake.
- Expansion into new indications, increasing utilization.
- Insurance reimbursement policies favoring cost reduction.
- Patent litigation and exclusivity periods.
Regulatory and Patent Considerations
Viatris’ product benefits from patent protections extending into the late 2020s. Patent expiry could trigger increased biosimilar entry, further impacting prices and market share.
Patent Expiry Schedule
- Basic patents typically expire around 2027-2028.
- Secondary patents and formulation protections may delay biosimilar competition until 2029.
Market Entry and Distribution Channels
Viatris primarily supplies through:
- Direct hospital and specialty clinic channels.
- Wholesale distributors.
- Physician offices for aesthetic procedures.
The distribution's competitive landscape influences effective pricing strategies.
Summary
NDC 59762-2858, aligned with Viatris’ botulinum toxin product, faces a data-rich environment with growing demand driven by therapeutic and aesthetic applications. Pricing is expected to decline gradually due to biosimilar competition while maintaining premium status in many markets due to brand recognition and indication breadth.
Key Takeaways
- The global botulinum toxin market is growing at a 7-9% CAGR, expected to reach approximately $6-7 billion by 2028.
- In the U.S., the baseline wholesale unit cost remains around $0.85-$1.20 per 100 units, with retail prices approximately 20-30% higher.
- Biosimilar competition will pressure prices downward, potentially reducing costs by 15-25%.
- Patent expiration, likely around 2027-2028, will open the market to biosimilar proliferation.
- New indications and expanded clinical use will sustain demand and mitigate some pricing pressures.
FAQs
1. What clinical indications does the product associated with NDC 59762-2858 serve?
It is approved for conditions including cervical dystonia, blepharospasm, hyperhidrosis, and glabellar lines.
2. How does biosimilar competition impact pricing prospects?
Biosimilar entry typically reduces prices by 15-25%, leading to downward pressure on both wholesale and retail rates.
3. What factors could delay patent expiration and affect market entry?
Patent litigation, secondary patents, and formulation protections can extend exclusivity beyond initial expiration estimates.
4. What regions are likely to see the fastest market growth?
North America and Europe lead growth due to high acceptance of aesthetic procedures and expanding therapeutic indications.
5. How might regulatory changes influence future pricing?
Reimbursement policies and approvals for new indications could increase utilization, moderating some price declines.
References
[1] Grand View Research. (2022). "Botulinum Toxin Market Size, Share & Trends."
[2] IQVIA. (2023). "Pharmaceutical Pricing & Reimbursement Data."
[3] MarketWatch. (2023). "Biosimilar Competition in Botulinum Toxins."
